サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1643910

組織工学の世界市場（2025年～2033年）

Global Tissue Engineering Market - 2025-2033

出版日
ページ情報
英文 197 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
組織工学の世界市場（2025年～2033年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の組織工学の市場規模は、2024年に189億米ドルに達し、2033年には651億米ドルに達すると予測され、予測期間2025年～2033年のCAGRは14.9%で成長する見込みです。

組織工学は、特定の病態がどのように進行し、どのように治療できるかを理解するための重要なツールです。生物工学は、生物学と工学の原理を組み合わせた幅広い学問分野です。生物工学は、生物学の研究に工学的なアプローチを取ると表現されることもあります。組織工学では、組織の開発、損傷、創傷治癒に関与する生物学的、物理的、化学的な力を研究します。

組織工学の目標は、患者の身体とシームレスに統合できる機能的な組織や器官を作製し、最終的に患者の転帰や生活の質を向上させることです。この分野には、足場ベースの技術、細胞ベースの治療法、生物活性分子送達システムなど、さまざまなアプローチが含まれます。

組織工学市場は、組織工学分野の進歩や組織工学への資金提供の増加により、一貫した成長を遂げています。例えば、2023年11月、SPRIND Funke Tissue Engineeringは、4つの意欲的なチームとともに、人工組織の主要特性を探求し実証する10ヶ月の旅を開始しました。SPRINDはこの画期的な研究を支援するため、最大50万ユーロの資金を提供しました。

市場力学：

促進要因と抑制要因

慢性疾患の増加

慢性疾患の増加傾向は、組織工学市場の成長を大きく後押ししており、予測期間中も市場を牽引すると予想されます。糖尿病、心血管疾患、変形性関節症、腎臓障害などの慢性疾患が世界的に増加するにつれて、組織工学を含む高度な治療オプションに対するニーズが高まっています。

例えば、WHOによると、毎年推定1,790万人が心血管疾患（CVD）で死亡しており、世界最大の死亡原因となっています。世界で4億2,200万人いる糖尿病患者の大部分は低・中所得国に住んでおり、この病気は年間150万人の死亡の直接の原因となっています。また、世界で約17億1,000万人が筋骨格系障害に苦しんでいます。数多くの慢性疾患の罹患率の上昇に伴い、組織工学のニーズは高まることが予想されます。

慢性疾患は多くの場合、従来の治療では修復しきれない組織の損傷や変性につながります。組織工学は、代替組織や臓器を作成し、治癒や再生を助けることで解決策を提供します。例えば、糖尿病患者は傷の治りが悪く、皮膚や血管の修復に組織工学が必要となります。

さらに、脳、肺、肝臓、骨の組織工学の開発は、がん転移の試験管内モデルの作成に有用です。組織工学は、転移巣における発がんと移動を直接調べる方法を提供するので、がん研究に革命を起こす可能性があります。血管新生を誘導することはがんの重要な特徴であり、新生血管は固形がんの形成と頻繁に関連しています。さらに、組織工学は、腫瘍微小環境とその複雑で多面的な特徴のすべてを再現することを可能にします。従って、がん患者の増加が組織工学の需要を押し上げています。

組織工学技術に伴う高コスト

組織工学技術に関連する高コストは、組織工学市場の成長を妨げる主な要因の一つです。組織工学は慢性疾患や組織損傷に対処するための有望な技術ですが、その開発、生産、実施にかかるコストは大きいです。例えば、米国国立衛生研究所（NIH）によれば、幹細胞を用いた組織工学的気道移植の総費用は、治療を受けた3人の英国人患者の場合、17万4,420米ドル～74万500米ドルでした。

3Dプリント技術を用いたバイオプリント組織の開発は、特殊なバイオプリント装置、高度なバイオマテリアル、熟練した技術者を必要とするため、非常にコスト集約的です。大きな可能性を秘めているとはいえ、この技術はまだ広く使用できるほど安価ではありません。例えば、ResearchGateによると、バイオプリント技術の価格は5,000米ドル～50万米ドル以上です。

目次

第1章 市場イントロダクションと範囲

  • レポートの目的
  • 調査のカバー範囲と定義
  • 調査の対象範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 材料タイプ別のスニペット
  • 技術別のスニペット
  • 用途別のスニペット
  • エンドユーザー別のスニペット
  • 地域別のスニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疾患の蔓延
    • 抑制要因
      • 組織工学技術に関連する高コスト
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 組織工学市場：材料タイプ別

  • 合成材料
    • ポリマー
    • ハイドロゲル
    • セラミック
    • 複合材料
  • 天然材料
    • 細胞外マトリックス（ECM）タンパク質
    • フィブリン
    • コラーゲン
    • シルク
  • ナノファイバー足場
  • タンパク質ベース材料
  • その他

第6章 組織工学市場：技術別

  • 生体材料と足場
  • 細胞培養
  • バイオリアクターと培養システム
  • バイオプリント
  • その他

第7章 組織工学市場：用途別

  • 筋骨格
  • 皮膚と外皮
  • 心臓病学
  • 神経学
  • その他

第8章 組織工学市場：エンドユーザー別

  • 病院と診療所
  • 契約開発製造企業
  • 研究・学術機関
  • バイオ技術および製薬企業

第9章 組織工学市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • 3D BioFibR Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • CollPlant Biotechnologies Ltd.
  • Lonza Group
  • InSphero AG
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Corning Incorporated
  • Prellis Biologics
  • Collagen Solutions（US）LLC
  • SunP BIOTECH
  • Cellink

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証とバリデーション

第13章 付録

目次
Product Code: BT6742

The global tissue engineering market reached US$ 18.9 billion in 2024 and is expected to reach US$ 65.1 billion by 2033, growing at a CAGR of 14.9% during the forecast period 2025-2033.

Tissue engineering is an important tool in understanding how certain conditions progress and how they can be treated. It is part of the field of bioengineering, a broad discipline that combines principles from biology and engineering. Bioengineering is sometimes described as taking an engineering approach to the study of biology. Tissue engineering involves investigating the biological, physical, and chemical forces involved in tissue development, injury, and wound healing.

The goal of tissue engineering is to fabricate functional tissues and organs that can integrate seamlessly with the patient's body, ultimately improving patient outcomes and quality of life. This field encompasses various approaches, including scaffold-based techniques, cell-based therapies and bioactive molecule delivery systems.

The tissue engineering market is experiencing consistent growth with advancements in the field of tissue engineering and rising funding for tissue engineering. For instance, in November 2023, SPRIND Funke Tissue Engineering launched a ten-month journey to explore and demonstrate the key characteristics of artificial tissue embarking with four ambitious teams. SPRIND provided up to EUR 500,000 in funding to support this groundbreaking work.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the tissue engineering market and is expected to drive the market over the forecast period. As chronic diseases such as diabetes, cardiovascular diseases, osteoarthritis and kidney disorders increase globally, the need for advanced treatment options, including tissue engineering, has grown.

For instance, according to the WHO, an estimated 17.9 million people die from cardiovascular diseases (CVDs) each year, making them the world's leading cause of mortality. The bulk of the 422 million individuals with diabetes globally reside in low- and middle-income nations, and the disease is directly responsible for 1.5 million fatalities annually. Around 1.71 billion people worldwide suffer from musculoskeletal disorders. The need for tissue engineering is expected to rise as a result of the rising incidence of numerous chronic illnesses.

Chronic diseases often lead to tissue damage or degeneration that traditional treatments cannot fully repair. Tissue engineering offers solutions by creating replacement tissues or organs, aiding in healing and regeneration. For instance, diabetic patients suffer from poor wound healing, necessitating tissue engineering for skin or vascular repair.

Additionally, developments in brain, lung, liver, and bone tissue engineering are useful for creating in vitro models of cancer metastasis. Because tissue engineering offers ways to directly examine carcinogenesis and migration at metastases, it has the potential to revolutionize cancer research. Since inducing angiogenesis is a key characteristic of cancer, neovascularization is frequently linked to the formation of solid tumors. Additionally, tissue engineering makes it possible to replicate the tumor microenvironment and all of its intricate and multifaceted features. Thus, rising cancer cases boosts the demand for tissue engineering.

High cost associated with the tissue engineering technique

The high cost associated with tissue engineering techniques is one of the major factors hampering the growth of the tissue engineering market. While tissue engineering holds promise for addressing chronic diseases and tissue damage, the costs involved in its development, production, and implementation are significant. For instance, according to the National Institute of Health (NIH), the total costs of stem cell-based tissue-engineered airway transplants for the three UK patients treated ranged from $174,420 to $740,500.

The development of bioprinted tissues using 3D printing technology is highly cost-intensive due to the need for specialized bioprinting machines, advanced biomaterials, and skilled technicians. While it holds significant potential, this technology is not yet affordable for widespread use. For instance, according to ResearchGate, bioprinting techniques prices range from $5,000 to over $500,000.

Segment Analysis

The global tissue engineering market is segmented based on material type, technology, application, end-user and region.

Technology:

The biomaterials and scaffolds segment is expected to dominate the tissue engineering market share

Biomaterials and scaffolds serve as the foundation for tissue regeneration by providing structural support for growing cells and promoting tissue formation. Biomaterials interact with biological systems to promote desired therapeutic outcomes, such as tissue regeneration, repair or replacement. In tissue engineering, biomaterials serve as scaffolds, carriers or matrices for cells and bioactive molecules, providing a supportive environment for tissue formation and integration. Thus, biomaterials and scaffolds are highly used for many research activities.

For instance, in November 2023, To conduct the research, Dr. ZHAO combined several disciplines, including material science, cell biology, engineering, and medicine. Her research focuses on modifying cell microenvironments, influencing cell behaviors, and promoting the growth of tissue-engineered organs. Her research team actively studies how cells perceive, interact, and evolve with biomaterials to restore diseased or damaged tissues to create patient-oriented biomaterials with distinctive shapes and properties.

Biomaterials serve as carriers for bioactive molecules, therapeutic agents or cells in tissue engineering applications. These biomaterials are used in bioprinting and pharmaceutical drug development. For instance, in September 2022, 3D Systems established Systemic Bio, a new, fully owned business. Systemic Bio will use biomaterials and human cells to produce incredibly accurate vascularized organ models by utilizing 3D Systems' innovative, production-level bioprinting technology. At the very beginning of the creation of new pharmaceutical drugs, these unique organs-on-chips can be produced in huge quantities with reproducible results and then perfused with any desired drug molecule to research drug metabolism and its effects on healthy or sick tissue.

Geographical Analysis

North America is expected to hold a significant position in the tissue engineering market share

North America is home to many leading companies in the tissue engineering space, which drive innovation and commercialization. These companies are involved in developing biomaterials, scaffolds, and cell-based therapies for various applications, including orthopedics, cardiovascular diseases, and wound healing.

Companies like Organovo, a leader in 3D bioprinting, Medtronic and other emerging players that develop advanced tissue engineering solutions, have strong presences in North America. The presence of these market leaders fosters a competitive environment that accelerates market growth.

For instance, in August 2024, CytoNest Inc. launched its first commercial product, a fiber scaffold that enhances tissue engineering and cell production. Applications for the product, known as CytoSurge 3D fiber scaffold, include cell research, biopharmaceutical cell therapies and the generation of cultured meat and seafood.

Asia-Pacific is growing at the fastest pace in the tissue engineering market

Tissue engineering in the Asia-Pacific region is expanding from research into clinical applications, with several companies and research institutions moving toward commercialization. The clinical application of tissue engineering technologies such as 3D bioprinting helps in treating conditions like skin burns, bone fractures, cartilage damage, organ failure and others are gaining momentum.

For instance, in November 2024, Scire Science, a biotech company based in Kochi, made history by introducing India's first patented domestic bioink for sophisticated 3D bioprinting applications. This invention positions Scire Science as an Indian leader in a field dominated by a small number of multinational corporations. With the use of sophisticated 3D bioprinting, this technique makes it possible to biofabricate the tissues of the liver, kidney, pancreas, skin, brain and heart.

Competitive Landscape

The major global players in the tissue engineering market include 3D BioFibR Inc., CollPlant Biotechnologies Ltd, Lonza Group, InSphero AG, Merck KGaA, Thermo Fisher Scientific Inc., Corning Incorporated, Prellis Biologics, Collagen Solutions (US) LLC, SunP BIOTECH, Cellink and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global tissue engineering market report delivers a detailed analysis with 73 key tables, more than 70 visually impactful figures, and 197 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost Associated with the Tissue Engineering Technique
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. SWOT Analysis
  • 4.9. Unmet Needs and Gaps
  • 4.10. Recommended Strategies for Market Entry and Expansion
  • 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.12. Pricing Analysis and Price Dynamics

5. Tissue Engineering Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Synthetic Materials*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Polymers
    • 5.2.4. Hydrogels
    • 5.2.5. Ceramics
    • 5.2.6. Composites
  • 5.3. Natural Materials
    • 5.3.1. Extracellular Matrix (ECM) Proteins
    • 5.3.2. Fibrin
    • 5.3.3. Collagen
    • 5.3.4. Silk
  • 5.4. Nanofiber Scaffolds
  • 5.5. Protein-Based Materials
  • 5.6. Others

6. Tissue Engineering Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Biomaterials and Scaffolds*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cell Culture
  • 6.4. Bioreactors and Culture Systems
  • 6.5. Bio-printing
  • 6.6. Others

7. Tissue Engineering Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Musculoskeletal*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Skin & Integumentary
  • 7.4. Cardiology
  • 7.5. Neurology
  • 7.6. Others

8. Tissue Engineering Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals and Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Contract Development and Manufacturing Organization
  • 8.4. Research and Academic Institutes
  • 8.5. Biotechnology and Pharmaceutical Companies

9. Tissue Engineering Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. 3D BioFibR Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. CollPlant Biotechnologies Ltd.
  • 11.3. Lonza Group
  • 11.4. InSphero AG
  • 11.5. Merck KGaA
  • 11.6. Thermo Fisher Scientific Inc.
  • 11.7. Corning Incorporated
  • 11.8. Prellis Biologics
  • 11.9. Collagen Solutions (US) LLC
  • 11.10. SunP BIOTECH
  • 11.11. Cellink

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us